Once-Weekly NNC0487-0111 Injections to Support Weight Loss in Adults with Obesity

What this Trial Is About

This research aims to find out if NNC0487-0111 is safe and effective for adults with excess body weight. The study compares this medicine to a placebo in people who have a history of unsuccessful attempts to lose weight through diet. It is a phase 3 clinical trial that evaluates treatment for obesity, focusing on weight loss and related health measures. Participants receive weekly injections under the skin with either NNC0487-0111 at one of four dose levels or a placebo. These injections are given using pre-filled pen-injectors to the thigh, abdomen, or upper arm. All participants follow a reduced-calorie diet and increase physical activity during the study. The trial lasts up to 136 weeks, with treatment and follow-up periods designed to assess long-term effects. Throughout the study, participants attend regular visits where researchers measure changes in body weight, waist circumference, blood pressure, blood sugar levels, cholesterol, and quality of life scores. Safety is monitored by tracking any adverse events during and after treatment. The main outcome is the relative change in body weight from the start of the study to week 84, with continued observation up to week 136. Participants remain under medical supervision throughout the trial.

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight